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Abstract
Gentamicin is extensively used in the treatment of severe Gram-negative bacterial infections. A loading dose of 7 mg/kg is recom-
mended to achieve a maximum concentration (Cmax) above 16 mg/L. We studied gentamicin pharmacokinetic data from patients treated
between January 2006 and June 2008 in two intensive-care units. The Sawchuk and Zaske one-compartment pharmacokinetic model
was used to estimate the gentamicin volume of distribution (the 32 patients had a median age of 68 years (23 men)). The median vol-
ume of distibution (Vd) per kilogram of body weight (Vd/kg) was 0.41 L/kg (interquartile range of 0.36–0.46 L/kg), with no correlations
with age, Charlson comorbidity score, sequential organ failure assessment (SOFA) score and creatinine serum level (r2 = 0.016, 0.058,
0.037, and 0.067, respectively). Women had a signiﬁcantly higher median Vd/kg (0.50 vs. 0.40 L/kg, p 0.002) and lower Cmax (15.2 vs.
18.5 mg/L, p 0.016), despite similar dose/kg. In a logistic regression model, only sex (female: OR 0.032; 95% CI 0.03–0.387) and dose/kg
(per mg/kg: OR 3.21; 95% CI 1.17–8.79) were signiﬁcantly associated with the achievement of Cmax above 16 mg/L. Gentamicin clear-
ance was 57 mL/min (interquartile range of 44.7–78 mL/min) and decreased with age (r2 = 0.178, p 0.016), SOFA score (r2 = 0.199,
p 0.011) and creatinine clearance (r2 = 0.258, p 0.003). Gentamicin Vd was increased in critically ill patients, particularly in women.
Therefore, high gentamicin loading doses should be given to all patients, especially women, independently of organ failure. Gentamicin
clearance decreases with age, SOFA score, and renal failure.
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Introduction
Gram-negative bacterial infections are responsible for
increased morbidity and mortality, mainly in critically ill
patients. Combination therapy with aminoglycosides, espe-
cially gentamicin, is widely recommended for treatment of
severe infections suspected of being caused by Gram-nega-
tive organisms, in order to increase the chance of adequate
empirical therapy. In severely septic patients, outcome is
related to how quickly effective antimicrobial therapy is
implemented [1]. Therefore, adequate antibiotic concentra-
tions should be achieved as soon as possible, even before
serum measurements can be obtained. The efﬁcacy of amino-
glycosides is related to maximum serum concentration
(Cmax). A Cmax as high as 20 mg/L gentamicin has been pro-
posed for treating hospital-acquired infections, and an initial
dose of at least 7 mg/kg was recommended to achieve such
a level [2]. However, in critically ill septic patients, the
increased extracellular volume and changes in protein binding
can cause a decrease in gentamicin serum concentrations
and consequent therapeutic failure [3].
These rapidly changing conditions, associated with thera-
peutic interventions such as aggressive ﬂuid resuscitation and
mechanical ventilation, can alter extracellular volume, the
rate of drug elimination, and, consequently, drug plasma lev-
els. These pathophysiological changes are also inﬂuenced by
the clinical course of the infection, resolving with successful
treatment or persisting if refractory to therapy. Therefore,
there is not only signiﬁcant interpatient variability, but also
intrapatient variability over time [4]. Consequently, a volume
of distibution (Vd) per kilogram of body weight (Vd/kg) of
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0.22–0.3 L/kg, calculated in the healthy population, may not
correctly predict gentamicin concentrations in septic
patients, in particular in the critically ill [3]. As a result,
extrapolation of a Vd/kg of 0.22–0.3 L/kg to assess gentamicin
pharmacokinetics in intensive-care patients could lead to
erroneous dose calculations and underdosing.
Furthermore, accumulation of aminoglycosides is associ-
ated with several adverse reactions, notably renal dysfunction.
Therefore, monitoring of aminoglycoside Cmax values prevents
underdosing and therapeutic failure, as well as overdosing and
toxicity. Studies addressing this issue sometimes combine
pharmacokinetic (PK) data from septic patients in different
stages of infection and with different durations of antibiotic
therapy [5,6]. The aim of our study was to measure gentami-
cin ﬁrst-dose pharmacokinetics in critically ill patients, in
order to deﬁne the ideal initial dose and schedule interval.
Materials and Methods
This study was performed in two medical/surgical intensive-
care units (ICUs) of tertiary hospitals (Sa˜o Francisco Xavier
Hospital and Sa˜o Jose´ Hospital, Lisbon, Portugal). We retro-
spectively studied gentamicin PK parameters in patients trea-
ted between January 2006 and June 2008. The decision to
start gentamicin was based on a proven or presumed sepsis
caused by Gram-negative bacteria. The institutional review
board of each hospital approved the study design and waived
the need for informed consent. The present study did not
interfere with any patient management decisions. The deci-
sion to start an aminoglycoside was always made by the
attending physician, who was unaware of the study. The data
collected included admission diagnosis, past medical history,
vital signs, and ICU and hospital outcome. Sequential organ
failure assessment (SOFA) [7] and Charlson comorbidity [8]
scores were also recorded.
Patients were eligible for inclusion in the study if they
received a gentamicin loading dose selected to achieve high
serum levels (a target Cmax of 16–24 mg/L) [9] and if PK data,
speciﬁcally peak and trough levels, were measured between)
the ﬁrst and second dose. Trough levels were measured to
determine the optimum antibiotic dosing interval. The
intended trough concentration was 0.5–1 mg/L. Gentamicin
was given as a continuous infusion lasting for 30–60 min. Peak
serum levels were measured 30 min after the end of gentami-
cin infusion [9]. Measurement of gentamicin serum concentra-
tions was performed by an immunoturbidimetric inhibition
technique, using a commercial kit (Dimension Vista System
Gent; Dade Behring, Newark, USA). The detection limit is
0.2 mg/L, and the coefﬁcient of variation is 4%.
The Sawchuk and Zaske one-compartment PK model [10]
was used to calculate gentamicin Vd/kg, elimination rate con-
stant (Kel) and clearance. Estimates of Cmax were obtained by
backward extrapolation of the measured peak concentration
to the end of the infusion, assuming a one-compartment model
and ﬁrst-order elimination kinetics. Elimination half-life (t1/2, in
hours) was calculated with the formula t1/2 = 0.693/Kel.
To estimate Vd/kg and dose/kg, ideal body weight (IBW)
plus 40% of the difference between actual weight and IBW
was used. IBW was calculated according to the Devine for-
mula (45.5 + (0.906 · (height in cm ) 152.9 cm)) plus 4.5 kg
if male). If the patient weight was less than IBW, the actual
body weight was used.
Gentamicin clearance was calculated with the formula
clearance = Kel · Vd. The Cockroft–Gault [11] and modiﬁed
diet in renal disease [12] methods were used to estimate
creatinine clearance. For this purpose, the serum creatinine
concentration was measured on the ﬁrst day of gentamicin
therapy. We assessed the inﬂuence of the above variables on
ﬁrst-dose gentamicin Cmax.
Statistical analyses
Standard descriptive statistics were used. Continuous vari-
ables were reported as medians (25–75% interquartile range
(IQR)), unless otherwise stated. Comparisons between
groups were performed with unpaired Student’s t-test, one-
way ANOVA, Mann–Whitney U-test or Kruskal–Wallis
H-test for continuous variables, according to data distribu-
tion. Post hoc multiple comparisons were performed with the
Bonferroni test. The chi-square test was used to make com-
parisons between categorical variables. Correlation coefﬁ-
cient (r) and coefﬁcient of determination (r2) were used to
determine the relationship between two numerical variables.
To determine which independently associated variables
best predicted a ﬁrst-dose gentamicin Cmax of at least 16 mg/
L, we created a multivariable logistic regression model. The
variables tested as predictors of a Cmax of at least 16 mg/L
were ICU outcome, admission diagnoses (medical, surgical,
trauma), SOFA score, sex, and gentamicin dose (mg/kg).
These were considered for the multivariable logistic regres-
sion model if they: (i) were statistically signiﬁcant in univariate
analyses (p <0.05); and (ii) had an OR of ‡1.2. Before studied
variables were entered into the logistic regression model,
multicolinearity among them was checked by computing the
correlation coefﬁcient (r) between variables taken two by two.
An r-value of <0.4 was considered low enough to exclude
correlation between the variables. Results were reported as
ORs with 95% CIs. Signiﬁcance was accepted for p <0.05.
Statistical analyses were performed with SPSS software
(version 13.0 for Windows; SPSS Inc., Chicago, Illinois, USA).
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Results
We studied 32 patients with a suspected or documented epi-
sode of Gram-negative bacterial sepsis (Table 1). Their med-
ian age was 68 years, and 23 were men. This was a severely
ill group of patients, with a median SOFA score of 8 and a
median Charlson comorbidity score of 4. The ICU mortality
rate was 28.1% (N = 9). The lung was the most common pri-
mary site of infection (N = 18); six patients had intra-abdom-
inal infection, and four had a central venous catheter-related
infection. The majority of patients were medical patients
(N = 20, 62.5%), six were surgical patients (non-trauma), and
ﬁve were trauma patients. Only one patient was classiﬁed as
neurosurgical. Twenty patients were on mechanical ventila-
tion, ten were on vasopressors, and three, with acute non-
oliguric renal failure, were on renal replacement therapy.
Patients were given a mean ﬁrst gentamicin dose of 7.4 mg/
kg (pharmacokinetic body weight) (Table 2) after a median
length of hospital stay of 15.5 days. A median Vd/kg of
0.41 L/kg (IQR 0.36–0.46 L/kg) was found (Table 3). Only six
patients had a Vd/kg of £0.22–0.3 L/kg, which is the normal
range for the healthy population [13].
We were unable to identify any signiﬁcant correlation
between Vd/kg and age (r
2 = 0.016), Charlson comorbidity
score (r2 = 0.058), SOFA score (r2 = 0.037), or creatinine
serum level (r2 = 0.067). The presence of mechanical ventila-
tion or septic shock had no inﬂuence on Vd/kg (p 0.59 and
p 0.14, respectively). We found a relationship with female
gender; women had a signiﬁcantly higher median Vd/kg (0.50
vs. 0.40 L/kg, p 0.002) and therefore a signiﬁcantly lower
Cmax (15.2 vs. 18.5 mg/L, p 0.016) (Fig. 1). This ﬁnding
was not the result of different gentamicin doses in male and
female patients (p 0.569).
Gentamicin maximum concentration
Only 21 of our patients (65.6%) achieved the target gentami-
cin Cmax concentration of at least 16 mg/L after the ﬁrst
dose. Of these, only ten patients (31.3%) had a concentration
higher than 20 mg/L.
We designed a logistic regression model to determine
factors associated with a gentamicin Cmax of at least 16 mg/L.
In this model, only gender (female: OR 0.032;
95% CI 0.03–0.387) and the dose/kg (per mg/kg: OR 3.21;
95% CI 1.17–8.79) were signiﬁcantly associated with achieve-
ment of a gentamicin Cmax above 16 mg/L.
Gentamicin clearance
In our group of septic patients, the median gentamicin
clearance was 57 mL/min (IQR 44.7–78.0 mL/min). The
TABLE 1. Baseline patient characteristics
Median Interquartile range
Age (years) 68 48–79
Gender: male/female 23/9
Creatinine (mg/dL) 0.9 0.6–1.8
SOFA score 8 4–11
Charlson score 4 2–6
Ideal body weight (kg) 73 66–85
SOFA, sequential organ failure assessment.
TABLE 2. Measured gentamicin pharmacokinetic parameters
Median Interquartile range
Dose (mg/kg) 7.4 6.7–8.1
Peak concentration (mg/L) 16.6 13.5–18.9
Trough concentration (mg/L) 0.8 0.6–2.1
Time to trough sample (h) 22.6 18.4–24
The peak concentration was deﬁned as the concentration measured at 30 min
after a 30–60-min gentamicin infusion.
TABLE 3. Calculated gentamicin pharmacokinetic parame-
ters
Median Interquartile range
Vd (L) 26.5 24.3–28.8
Vd/kg (L/kg) 0.41 0.36–0.46
Cmax (mg/L) 17.8 14.5–20.6
t1/2 (h) 5.0 3.3–7.3
Kel (per hour) 0.14 0.1–0.2
Creatinine clearance (mL/min)
CG 80.7 33–136
MDRD 90.4 41–130
Gentamicin clearance (mL/min) 57 44.7–78
Vd, volume of distribution; Cmax, estimated maximum serum concentration at
the end of gentamicin infusion; t1/2, half-life; Kel, elimination rate constant; CG,
Cockroft–Gault; MDRD, modiﬁed diet in renal disease.
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FIG. 1. Relationship between gender and Vd/kg of gentamicin.
Women have a signiﬁcantly higher Vd/kg.
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gentamicin concentration proﬁle after the ﬁrst dose is shown
in Fig. 2. In patients on mechanical ventilation and with septic
shock, we found a lower gentamicin clearance (55.0 vs.
61.7 mL/min, p 0.9 and 51.7 vs. 65.0 mL/min, p 0.039,
respectively). However, it was higher in trauma patients than
in medical and surgical patients (71.7 vs. 55.0 vs. 55.0 mL/
min, p 0.3, respectively). Trough levels were measured at a
median of 22.6 h after the loading dose. At that time, three
patients had already a concentration below the detection
limit. Finally, we found that gentamicin clearance decreased
with age (r2 = 0.178, p 0.016), SOFA score (r2 = 0.199,
p 0.011), and also creatinine clearance, calculated with either
the Cockroft–Gault method (r2 = 0.258, p 0.003) or modi-
ﬁed diet in renal disease method (r2 = 0.173, p 0.018).
Discussion
Our study, performed in a heterogeneous population of criti-
cally ill patients with suspected Gram-negative bacterial sep-
sis, clearly showed an elevated ﬁrst-dose Vd/kg of gentamicin,
0.41 L/kg, in comparison with the healthy population. This
resulted in lower Cmax values, despite the use of loading
doses of 7.4 mg/kg. These results had no signiﬁcant correla-
tion with severity of infection, degree of organ dysfunction,
or presence of comorbidities. Moreover, females, even those
receiving similar gentamicin doses, had higher Vd/kg values,
and consequently lower Cmax values, than males. In fact, only
65.6% of our patients achieved the minimum target gentamicin
Cmax. In a logistic regression model, only the dose/kg (per
mg/kg: OR 3.21) predicted the achievement of a Cmax above
16 mg/L, and female gender (OR 0.032) inversely impacted
on that goal. Finally, we showed that gentamicin clearance
was inﬂuenced by age, organ dysfunction, and creatinine
clearance.
Sepsis and related therapeutic interventions, such as vol-
ume resuscitation, contribute to a signiﬁcant increase in the
Vd/kg of aminoglycosides [14,15], with a consequent reduc-
tion of Cmax. Therefore, the ﬁrst-dose gentamicin concentra-
tion should be higher in this patient population [3].
In another study of gentamicin pharmacokinetics in 79
critically ill patients [16], the Vd/kg was found to be signiﬁ-
cantly higher than in a non-septic control group (0.43 vs.
0.29 L/kg) and similar to our ﬁndings (0.41 L/kg). This differ-
ence correlated with the acute physiological score (r = 0.34,
p <0.01) and the cardiac index (r = 0.39, p <0.01). There-
fore, hyperdynamic septic patients, with a higher cardiac out-
put, were at increased risk of underdosing. Furthermore,
patients with preserved renal function had lower mean gen-
tamicin t1/2 than the control group [16]. In sepsis, particularly
in younger patients, increased renal clearance is occasionally
seen [14], leading to long periods without antibiotic expo-
sure. In our study, three patients (9.4%) had an undetectable
trough level at the time of dosing (a median of 22.6 h after
the start of infusion) suggesting a shorter gentamicin t1/2.
As we have already discussed, PK parameters probably
change over the infection course. This was clearly demon-
strated by Mann et al. [17], who reported a progressive
decrease in aminoglycoside clearance in critically ill patients
over time, underlining the need to monitor gentamicin serum
levels during therapy.
In another study of 40 critically ill patients, gentamicin Vd/kg,
calculated in the ﬁrst 48 h of therapy, was 0.43 L/kg [4], which
is again very similar to our ﬁndings. In contrast, in the same
study, on day 7 of therapy, Vd/kg was signiﬁcantly lower
(0.29 L/kg, p <0.001), and very close to values in the healthy
population. Such a marked decrease (>35%) in only 7 days
reﬂects the PK variations in these patients, and again under-
lines the need for close PK monitoring to achieve an adequate
Cmax and avoid toxicity. This strategy has been shown to
improve the achievement of plasma target concentrations [18].
An increase of Vd/kg (0.32l/kg) was also found in a group
of critically ill surgical patients [19]. An even higher Vd/kg
(0.76l/kg) was found by Rea et al. [20] in a mixed critically ill
population. In their study, only 20% of patients had a genta-
micin Cmax higher than 20 mg/L, despite receiving a dose of
7 mg/kg.
Despite the use of these high doses in critically ill patients,
an adequate ratio between Cmax and the bacterial gentamicin
MIC may not be achieved, because of the increased Vd/kg. In
our study, only 65.6% of patients had a gentamicin Cmax
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FIG. 2. Time course of gentamicin concentrations on the ﬁrst day
of therapy, assuming a one-compartment pharmacokinetic model and
ﬁrst-order elimination kinetics. The coefﬁcients of variation of Cmax
and trough concentration were 0.24 and 1.22, respectively. Target
Cmax range is deﬁned by the solid lines (16–24 mg/L).
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above 16 mg/L, and only 31.3% a concentration above
20 mg/L. The failure to achieve these target concentrations
is associated with poor outcome. In fact, there is a close
relationship between Cmax/MIC and outcome [21,22]. There-
fore, a reduction in Cmax and/or an increase in MIC may lead
to therapeutic failure.
Even in non-critically ill patients, high doses may be neces-
sary. Using the Monte Carlo simulation methodology, Nico-
lau et al. [2], assuming a Vd/kg of 0.2–0.3 L/kg, calculated that
a gentamicin dose of at least 7 mg/kg was required to
achieve a Cmax/MIC ratio of at least 10 for the treatment of
Gram-negative bacilli (essentially Pseudomonas) with gentami-
cin MICs of <2 mg/L. Using their aminoglycoside PK data,
the authors were able to draw a normogram to adjust
dosage interval according to serum concentration [2].
Zaske et al. [23], who studied a less sick patient popula-
tion, found a lower Vd/kg, with males having a slightly higher
value (0.21 vs. 0.19 L/kg, p <0.001). Our patient population,
a more severely ill group, had a Vd/kg double this (0.41 L/kg),
and values were signiﬁcantly higher in females. However, the
number of women included in our study was small (n = 9).
In the study of Zaske et al. [23], a signiﬁcant interpatient
variation in t1/2 was found, even in patients with normal
renal function, with a range of 0.4–7.6 h. These authors
were also unable to ﬁnd a correlation between renal failure
and Vd/kg, emphasizing the need to use maximum loading
doses.
The fear among clinicians of ototoxicity or nephrotoxicity
may inhibit the use of high doses of aminoglycosides even in
severe sepsis. Nevertheless, in studies evaluating gentamicin
dosage regimens, toxicity was similar or even less in patient
groups receiving high doses at longer intervals than in those
with standard dosing regimens [24,25].
Our study has several limitations, due to its observational
nature. The population studied was relatively small and het-
erogeneous. Moreover, body weight was usually measured
on the day of admission, and not on the day of sampling.
However, the study also has some strengths. All patients
were critically ill and had their PK samples collected on the
ﬁrst day of gentamicin therapy. This results in more uniform
PK data and more homogeneous results. In addition, these
results were compared with clinical data, making them clini-
cally more useful.
In conclusion, in critically ill patients with severe sepsis
and septic shock with a suspicion of Gram-negative bacterial
infection, the gentamicin Vd/kg cannot be predicted by age,
the presence of renal failure, or any studied comorbidities.
Therefore, in order to obtain adequate serum concentra-
tions of gentamicin as soon as possible, a high ﬁrst gentami-
cin dose (i.e. at least 7 mg/kg) should be given to all patients,
regardless of the presence of organ dysfunction/failure. In
women, even higher doses may be needed.
In younger patients with normal renal function, dosing
intervals shorter than 24 h should be considered, to prevent
underdosing, whereas older patients should receive the
standard doses at longer intervals.
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